JP2011524417A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524417A5 JP2011524417A5 JP2011514633A JP2011514633A JP2011524417A5 JP 2011524417 A5 JP2011524417 A5 JP 2011524417A5 JP 2011514633 A JP2011514633 A JP 2011514633A JP 2011514633 A JP2011514633 A JP 2011514633A JP 2011524417 A5 JP2011524417 A5 JP 2011524417A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- immunogenic composition
- therapeutic agent
- ssea
- adjuvant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000002163 immunogen Effects 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 12
- 229940124597 therapeutic agent Drugs 0.000 claims 12
- 206010006187 Breast cancer Diseases 0.000 claims 8
- 208000026310 Breast neoplasm Diseases 0.000 claims 8
- 239000002671 adjuvant Substances 0.000 claims 8
- 239000000427 antigen Substances 0.000 claims 8
- 102000036639 antigens Human genes 0.000 claims 8
- 108091007433 antigens Proteins 0.000 claims 8
- 210000000130 stem cell Anatomy 0.000 claims 8
- 229940022399 cancer vaccine Drugs 0.000 claims 7
- 238000009566 cancer vaccine Methods 0.000 claims 7
- 206010028980 Neoplasm Diseases 0.000 claims 6
- VQFKFAKEUMHBLV-BYSUZVQFSA-N 1-O-(alpha-D-galactosyl)-N-hexacosanoylphytosphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)[C@H](O)CCCCCCCCCCCCCC)CO[C@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQFKFAKEUMHBLV-BYSUZVQFSA-N 0.000 claims 4
- 102000014914 Carrier Proteins Human genes 0.000 claims 4
- 108010078791 Carrier Proteins Proteins 0.000 claims 4
- 229930186217 Glycolipid Natural products 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 4
- 210000004443 dendritic cell Anatomy 0.000 claims 4
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 claims 3
- 230000028993 immune response Effects 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- 102100036013 Antigen-presenting glycoprotein CD1d Human genes 0.000 claims 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 2
- 101000716121 Homo sapiens Antigen-presenting glycoprotein CD1d Proteins 0.000 claims 2
- 229940098773 bovine serum albumin Drugs 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 230000013020 embryo development Effects 0.000 claims 2
- 210000002919 epithelial cell Anatomy 0.000 claims 2
- 229960000814 tetanus toxoid Drugs 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 206010008342 Cervix carcinoma Diseases 0.000 claims 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 claims 1
- 102000016607 Diphtheria Toxin Human genes 0.000 claims 1
- 108010053187 Diphtheria Toxin Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 208000003445 Mouth Neoplasms Diseases 0.000 claims 1
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 206010060862 Prostate cancer Diseases 0.000 claims 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 208000000453 Skin Neoplasms Diseases 0.000 claims 1
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 1
- 230000024932 T cell mediated immunity Effects 0.000 claims 1
- 206010043376 Tetanus Diseases 0.000 claims 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000001093 anti-cancer Effects 0.000 claims 1
- 201000010881 cervical cancer Diseases 0.000 claims 1
- 238000003776 cleavage reaction Methods 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 206010017758 gastric cancer Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 239000003966 growth inhibitor Substances 0.000 claims 1
- 230000028996 humoral immune response Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 claims 1
- 101710135378 pH 6 antigen Proteins 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 210000002307 prostate Anatomy 0.000 claims 1
- 230000007017 scission Effects 0.000 claims 1
- 201000000849 skin cancer Diseases 0.000 claims 1
- 201000011549 stomach cancer Diseases 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
- 201000005112 urinary bladder cancer Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6196808P | 2008-06-16 | 2008-06-16 | |
| US61/061,968 | 2008-06-16 | ||
| US12/485,546 | 2009-06-16 | ||
| US12/485,546 US20090317411A1 (en) | 2008-06-16 | 2009-06-16 | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| PCT/US2009/004519 WO2010005598A1 (en) | 2008-06-16 | 2009-08-06 | Globo h and related anti-cancer vaccines with novel glycolipid adjuvants |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014035431A Division JP5795655B2 (ja) | 2008-06-16 | 2014-02-26 | ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011524417A JP2011524417A (ja) | 2011-09-01 |
| JP2011524417A5 true JP2011524417A5 (enExample) | 2012-09-20 |
| JP5628158B2 JP5628158B2 (ja) | 2014-11-19 |
Family
ID=41431519
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513760A Pending JP2011524375A (ja) | 2008-06-16 | 2009-06-16 | ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用 |
| JP2011514633A Active JP5628158B2 (ja) | 2008-06-16 | 2009-08-06 | ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン |
| JP2014035431A Active JP5795655B2 (ja) | 2008-06-16 | 2014-02-26 | ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン |
| JP2015159196A Active JP6151319B2 (ja) | 2008-06-16 | 2015-08-11 | ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011513760A Pending JP2011524375A (ja) | 2008-06-16 | 2009-06-16 | ＧｌｏｂｏＨおよびＳＳＥＡ３に特異的な免疫反応を誘起する組成物および癌治療におけるその使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014035431A Active JP5795655B2 (ja) | 2008-06-16 | 2014-02-26 | ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン |
| JP2015159196A Active JP6151319B2 (ja) | 2008-06-16 | 2015-08-11 | ＧｌｏｂｏＨおよび新規な糖脂質アジュバントを有する関連抗がんワクチン |
Country Status (11)
| Country | Link |
|---|---|
| US (4) | US20090317411A1 (enExample) |
| EP (2) | EP2303286A4 (enExample) |
| JP (4) | JP2011524375A (enExample) |
| KR (1) | KR20110031949A (enExample) |
| CN (1) | CN102065868A (enExample) |
| AU (2) | AU2009268937A1 (enExample) |
| CA (2) | CA2728344A1 (enExample) |
| ES (1) | ES2570630T3 (enExample) |
| MX (2) | MX350230B (enExample) |
| NZ (1) | NZ590140A (enExample) |
| WO (2) | WO2010005735A2 (enExample) |
Families Citing this family (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7960139B2 (en) | 2007-03-23 | 2011-06-14 | Academia Sinica | Alkynyl sugar analogs for the labeling and visualization of glycoconjugates in cells |
| CN102076865B (zh) | 2008-05-02 | 2016-03-16 | 西雅图基因公司 | 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物 |
| MX2010013931A (es) * | 2008-06-16 | 2011-06-01 | Academia Sinica | Diagnosis de cancer basada en niveles de anticuerpos contra globo h y sus fragmentos. |
| CA2728344A1 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| US8680020B2 (en) | 2008-07-15 | 2014-03-25 | Academia Sinica | Glycan arrays on PTFE-like aluminum coated glass slides and related methods |
| US10087236B2 (en) | 2009-12-02 | 2018-10-02 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US11377485B2 (en) | 2009-12-02 | 2022-07-05 | Academia Sinica | Methods for modifying human antibodies by glycan engineering |
| US10338069B2 (en) | 2010-04-12 | 2019-07-02 | Academia Sinica | Glycan arrays for high throughput screening of viruses |
| ES2550853T3 (es) | 2010-05-03 | 2015-11-12 | Dcb-Usa Llc | Conjugación de polisacárido con enterotoxina termolábil (LT) de E. coli desintoxicada usada como vacuna |
| CN103108654A (zh) * | 2010-06-11 | 2013-05-15 | 索隆-基特林癌症研究协会 | 多价糖肽构建体及其用途 |
| WO2012019165A2 (en) | 2010-08-05 | 2012-02-09 | Seattle Genetics, Inc. | Methods of inhibition of protein fucosylation in vivo using fucose analogs |
| GB201013767D0 (en) * | 2010-08-17 | 2010-09-29 | Isis Innovation | Identification of ligands and their use |
| US20120288525A1 (en) | 2011-05-11 | 2012-11-15 | Chakravarty Sumana | Pharmaceutical compositions comprising attenuated plasmodium sporozoites and glycolipid adjuvants |
| WO2013133220A1 (ja) * | 2012-03-08 | 2013-09-12 | 学校法人産業医科大学 | がんの悪性度の試験方法、ならびに多能性を有する造腫瘍細胞およびその調製方法 |
| US10130714B2 (en) | 2012-04-14 | 2018-11-20 | Academia Sinica | Enhanced anti-influenza agents conjugated with anti-inflammatory activity |
| EP2885311B1 (en) | 2012-08-18 | 2020-01-01 | Academia Sinica | Cell-permeable probes for identification and imaging of sialidases |
| CA2883168A1 (en) | 2012-08-21 | 2014-02-27 | Academia Sinica | Benzocyclooctyne compounds and uses thereof |
| CA2882725C (en) | 2012-08-23 | 2021-03-09 | Regents Of The University Of Minnesota | Treatment of sickle cell disease and inflammatory conditions |
| CA3044471C (en) * | 2013-01-04 | 2021-05-11 | Obi Pharma, Inc. | Vaccines with higher carbohydrate antigen density and novel saponin adjuvant |
| JP6143240B2 (ja) | 2013-05-02 | 2017-06-07 | 国立研究開発法人産業技術総合研究所 | 糖鎖抗原の免疫誘導剤 |
| EP3013365B1 (en) * | 2013-06-26 | 2019-06-05 | Academia Sinica | Rm2 antigens and use thereof |
| US9981030B2 (en) | 2013-06-27 | 2018-05-29 | Academia Sinica | Glycan conjugates and use thereof |
| GB201313352D0 (en) | 2013-07-26 | 2013-09-11 | Isis Innovation | Identification of peptide ligands |
| KR102298172B1 (ko) | 2013-09-06 | 2021-09-06 | 아카데미아 시니카 | 변화된 글리코실 그룹을 갖는 당지질을 사용한 인간 iNKT 세포 활성화 |
| JP6431920B2 (ja) | 2013-09-17 | 2018-11-28 | オービーアイ ファーマ，インコーポレイテッド | 免疫反応を誘導する炭水化物ワクチンの組成とがんの治療におけるその使用 |
| KR20160104727A (ko) | 2014-01-16 | 2016-09-05 | 아카데미아 시니카 | 암의 치료 및 검출을 위한 조성물 및 방법 |
| WO2016114819A1 (en) * | 2015-01-16 | 2016-07-21 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10150818B2 (en) | 2014-01-16 | 2018-12-11 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| WO2015143126A1 (en) | 2014-03-19 | 2015-09-24 | Mackay Memorial Hospital Of Taiwan Presbyterian Church And Mackay Memorial Social Work Foundation | Immunogenic glycopeptides, composition comprising the glycopeptides and use thereof |
| TWI797430B (zh) | 2014-03-27 | 2023-04-01 | 中央研究院 | 反應性標記化合物及其用途 |
| SG11201607258SA (en) * | 2014-04-10 | 2016-10-28 | Obi Pharma Inc | Antibodies, pharmaceutical compositions and uses thereof |
| US10118969B2 (en) | 2014-05-27 | 2018-11-06 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| US10005847B2 (en) | 2014-05-27 | 2018-06-26 | Academia Sinica | Anti-HER2 glycoantibodies and uses thereof |
| KR20240096599A (ko) | 2014-05-27 | 2024-06-26 | 아카데미아 시니카 | 항-ｃｄ20 글리코항체 및 이의 용도 |
| AU2015267052A1 (en) | 2014-05-27 | 2016-12-15 | Academia Sinica | Compositions and methods relating to universal glycoforms for enhanced antibody efficacy |
| JP7063538B2 (ja) | 2014-05-28 | 2022-05-09 | アカデミア シニカ | 抗ＴＮＦα糖操作抗体群およびその使用 |
| GB201414021D0 (en) * | 2014-08-07 | 2014-09-24 | Nascient Ltd | Biological materials and uses thereof |
| US10155823B2 (en) | 2014-08-22 | 2018-12-18 | Academia Sinica | Glycan conjugates and use thereof |
| CN107001404B (zh) * | 2014-09-08 | 2021-06-29 | 中央研究院 | 使用醣脂激活人类iNKT细胞 |
| ES2797747T3 (es) * | 2014-09-15 | 2020-12-03 | Obi Pharma Inc | Composiciones de glucoconjugado inmunogénicas/terapéuticas y usos de las mismas |
| WO2016044164A1 (en) * | 2014-09-15 | 2016-03-24 | Wayne State University | Novel synthetic anticancer, antifungal, and antibacterial vaccines |
| US9975965B2 (en) | 2015-01-16 | 2018-05-22 | Academia Sinica | Compositions and methods for treatment and detection of cancers |
| US10495645B2 (en) | 2015-01-16 | 2019-12-03 | Academia Sinica | Cancer markers and methods of use thereof |
| TWI736523B (zh) | 2015-01-24 | 2021-08-21 | 中央研究院 | 新穎聚醣結合物及其使用方法 |
| CN107430127B (zh) * | 2015-01-24 | 2020-08-28 | 中央研究院 | 癌症标记及其使用方法 |
| TWI717333B (zh) | 2015-01-30 | 2021-02-01 | 中央研究院 | 增進抗體功效之通用糖型組合物及方法 |
| CN105067813A (zh) * | 2015-07-23 | 2015-11-18 | 丁晓昆 | 一种快速检测t-合酶活性的方法 |
| JP2018532990A (ja) * | 2015-09-04 | 2018-11-08 | オービーアイ ファーマ，インコーポレイテッド | グリカンアレイおよび使用の方法 |
| CA3016170A1 (en) | 2016-03-08 | 2017-09-14 | Academia Sinica | Methods for modular synthesis of n-glycans and arrays thereof |
| US10980894B2 (en) | 2016-03-29 | 2021-04-20 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| WO2017172990A1 (en) | 2016-03-29 | 2017-10-05 | Obi Pharma, Inc. | Antibodies, pharmaceutical compositions and methods |
| MY200886A (en) * | 2016-04-22 | 2024-01-22 | Obi Pharma Inc | Cancer Immunotherapy by Immune Activation or Immune Modulation Via Globo Series Antigens |
| JP2019527690A (ja) * | 2016-07-27 | 2019-10-03 | オービーアイ ファーマ，インコーポレイテッド | 免疫原性／治療用グリカン組成物およびその使用 |
| US11643456B2 (en) | 2016-07-29 | 2023-05-09 | Obi Pharma, Inc. | Human antibodies, pharmaceutical compositions and methods |
| AU2017316663B2 (en) | 2016-08-22 | 2024-02-22 | CHO Pharma Inc. | Antibodies, binding fragments, and methods of use |
| TW201825522A (zh) * | 2016-09-23 | 2018-07-16 | 張志隆 | 抗-globo h 抗體 |
| TWI767959B (zh) * | 2016-11-21 | 2022-06-21 | 台灣浩鼎生技股份有限公司 | 共軛生物分子、醫藥組成物及方法 |
| WO2019217951A1 (en) * | 2018-05-11 | 2019-11-14 | Obi Pharma Inc. | Method for predicting human immune response |
| WO2020006176A1 (en) | 2018-06-27 | 2020-01-02 | Obi Pharma, Inc. | Glycosynthase variants for glycoprotein engineering and methods of use |
| ES2992864T3 (en) | 2018-11-02 | 2024-12-18 | Siemens Healthcare Diagnostics Inc | Binding competitors for use in macrophilin-binding pharmaceutical assays and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544952B1 (en) * | 1994-03-15 | 2003-04-08 | Sloan-Kettering Institute For Cancer Research | Synthesis of glycoconjugates of the globo-H epitope and uses thereof |
| US20040126381A1 (en) * | 1996-04-23 | 2004-07-01 | Xin-Xing Gu | Intranasal immunization with detoxified lipooligosaccharide from nontypeable haemophilus influenzae or moraxella |
| AU750701C (en) * | 1997-04-16 | 2003-03-20 | Sloan-Kettering Institute For Cancer Research | Alpha-O-linked glycoconjugates, methods of preparation and uses thereof |
| WO2001065261A1 (en) * | 2000-02-29 | 2001-09-07 | Sloan-Kettering Institute For Cancer Research | Affinity matrix bearing tumor-associated antigens |
| GB0108364D0 (en) * | 2001-04-03 | 2001-05-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| GB0024200D0 (en) * | 2000-10-03 | 2000-11-15 | Smithkline Beecham Sa | Component vaccine |
| WO2003003985A2 (en) | 2001-07-06 | 2003-01-16 | Sloan-Kettering Institute For Cancer Research | Polyvalent conjugate vaccine for cancer |
| CA2453880A1 (en) * | 2001-07-25 | 2003-02-06 | New York University | Use of glycosylceramides as adjuvants for vaccines against infections and cancer |
| US7132101B2 (en) * | 2002-02-27 | 2006-11-07 | Duquesne University Of The Holy Ghost | Compositions and methods for eliciting an immune response to gram-negative bacterial infections |
| CA2500478A1 (en) * | 2002-09-27 | 2004-04-08 | Biomira, Inc. | Glycosylceramide analogues |
| US20060035267A1 (en) * | 2003-04-09 | 2006-02-16 | Livingston Philip O | Optimal polyvalent vaccine for cancer |
| GB0313916D0 (en) * | 2003-06-16 | 2003-07-23 | Glaxosmithkline Biolog Sa | Vaccine composition |
| WO2006068758A2 (en) * | 2004-11-19 | 2006-06-29 | The Scripps Research Institute | Detection, prevention and treatment of breast cancer |
| GB0428394D0 (en) | 2004-12-24 | 2005-02-02 | Chiron Srl | Saccharide conjugate vaccines |
| EP1833489A4 (en) | 2004-12-28 | 2011-08-03 | Univ Rockefeller | GLYCOLIPIDES AND ANALOGUE THEREOF AS ANTIGENS FOR NK-T CELLS |
| US7923013B2 (en) | 2004-12-28 | 2011-04-12 | The Rockefeller University | Glycolipids and analogues thereof as antigens for NKT cells |
| KR100764678B1 (ko) * | 2005-07-13 | 2007-10-09 | 재단법인서울대학교산학협력재단 | 알파-갈락토실세라마이드를 아쥬반트로 포함하는 비강투여용 백신 조성물 |
| JP5564672B2 (ja) * | 2006-06-30 | 2014-07-30 | ザ スクリプス リサーチ インスティテュート | アジュバント及びその使用方法 |
| CN101225383B (zh) * | 2007-01-15 | 2011-10-12 | 燕秋 | 用于抑制LeY糖抗原合成的岩藻糖基转移酶Ⅰ和Ⅳ的RNA干涉序列及重组干涉质粒 |
| GB0703369D0 (en) * | 2007-02-21 | 2007-03-28 | Health Prot Agency | Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines |
| EP2112930B1 (en) * | 2007-02-21 | 2017-01-11 | Vaccinex, Inc. | Modulation of nkt cell activity with antigen-loaded cdid molecules |
| WO2008128207A1 (en) * | 2007-04-13 | 2008-10-23 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
| US20100203137A1 (en) * | 2007-06-04 | 2010-08-12 | Mario Contorni | Formulation of meningitis vaccines |
| CA2728344A1 (en) * | 2008-06-16 | 2010-01-14 | Academia Sinica | Compositions for inducing immune responses specific to globo h and ssea3 and uses thereof in cancer treatment |
| US8383767B2 (en) * | 2008-06-27 | 2013-02-26 | Academia Sinica | Immunogenic protein carrier containing an antigen presenting cell binding domain and a cysteine-rich domain |
| US7928077B2 (en) * | 2008-07-11 | 2011-04-19 | Academia Sinica | Alpha-galactosyl ceramide analogs and their use as immunotherapies |
-
2009
- 2009-06-16 CA CA2728344A patent/CA2728344A1/en not_active Abandoned
- 2009-06-16 US US12/485,546 patent/US20090317411A1/en not_active Abandoned
- 2009-06-16 EP EP09794927A patent/EP2303286A4/en not_active Withdrawn
- 2009-06-16 JP JP2011513760A patent/JP2011524375A/ja active Pending
- 2009-06-16 CN CN2009801237219A patent/CN102065868A/zh active Pending
- 2009-06-16 WO PCT/US2009/047537 patent/WO2010005735A2/en not_active Ceased
- 2009-06-16 AU AU2009268937A patent/AU2009268937A1/en not_active Abandoned
- 2009-06-16 KR KR1020117001004A patent/KR20110031949A/ko not_active Withdrawn
- 2009-08-06 WO PCT/US2009/004519 patent/WO2010005598A1/en not_active Ceased
- 2009-08-06 MX MX2014004316A patent/MX350230B/es unknown
- 2009-08-06 EP EP09789075.0A patent/EP2310047B1/en active Active
- 2009-08-06 AU AU2009269127A patent/AU2009269127B2/en active Active
- 2009-08-06 ES ES09789075T patent/ES2570630T3/es active Active
- 2009-08-06 NZ NZ590140A patent/NZ590140A/en unknown
- 2009-08-06 US US12/537,129 patent/US8268969B2/en active Active
- 2009-08-06 CA CA2728341A patent/CA2728341C/en active Active
- 2009-08-06 JP JP2011514633A patent/JP5628158B2/ja active Active
- 2009-08-06 MX MX2010013932A patent/MX2010013932A/es active IP Right Grant
-
2012
- 2012-08-07 US US13/568,510 patent/US9028836B2/en active Active
-
2014
- 2014-02-26 JP JP2014035431A patent/JP5795655B2/ja active Active
-
2015
- 2015-04-01 US US14/675,838 patent/US9603913B2/en active Active
- 2015-08-11 JP JP2015159196A patent/JP6151319B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2011524417A5 (enExample) | ||
| Ejazi et al. | Mechanisms of nanoparticle transport across intestinal tissue: an oral delivery perspective | |
| Feng et al. | Recent advance in tumor-associated carbohydrate antigens (TACAs)-based antitumor vaccines | |
| JP2013528229A5 (enExample) | ||
| Raghuwanshi et al. | Dendritic cell targeted chitosan nanoparticles for nasal DNA immunization against SARS CoV nucleocapsid protein | |
| JP2018502885A5 (enExample) | ||
| AU2014366842B2 (en) | Method of synthesis of silica vesicles and use thereof | |
| CN110064050B (zh) | 含STn或F-STn的糖缀合物及其制备方法和在抗肿瘤疫苗中的应用 | |
| RU2015131033A (ru) | Вакцины с повышенной плотностью размещения углеводного антигена и новый сапониновый адъювант | |
| Fernandez-Tejada et al. | Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol | |
| JP2019527690A5 (enExample) | ||
| US20240131152A1 (en) | Nano-particles that contain synthetic variants of gm3 ganglioside as adjuvants in vaccines | |
| CN106659799A (zh) | 用于制备针对因肠致病性细菌引起的感染的广谱疫苗的包含表达内置的多个表位的分子构建体的基本单元的糖缀合物疫苗 | |
| Wallis et al. | A liposome-based cancer vaccine for a rapid and high-titre anti-ErbB-2 antibody response | |
| US20080038329A1 (en) | T-cell activating agent | |
| TWI392502B (zh) | 聚己醣抗原及含新穎醣脂質佐劑之相關抗癌疫苗 | |
| US20240042000A1 (en) | Carbohydrate structures and uses thereof | |
| CN104225589B (zh) | 一种缀合疫苗及其制备方法 | |
| CN104258387B (zh) | 人用轮状病毒疫苗及其制备方法 | |
| Toth et al. | Recent advances in design and synthesis of self-adjuvanting lipopeptide vaccines | |
| AU2021204628B2 (en) | Methods and compositions related to accelerated humoral affinity | |
| CN104606674B (zh) | 轮状病毒多糖‑蛋白结合疫苗及其制备方法 | |
| CN104208671B (zh) | 一种肺炎多价结合疫苗及其制备方法 | |
| Emam et al. | Using PEGylated antigen-expressing extracellular vesicles to accomplish splenic B cell-targeted antigen delivery for induction of antibodies against SARS-CoV-2 spike protein | |
| CN116650634A (zh) | 一种免疫佐剂和应用 |